Interference by interferons: Janus faces in vascular proliferative diseases.
Interferons (IFNs) display pleiotropic properties; not only do they protect cells from viral infections but they may also modulate cell growth and differentiation as well as innate and adaptive immune responses. Therapeutic applications of IFNs have proven efficacy in a variety of illnesses, including hepatitis, multiple sclerosis, and some forms of cancer. Emerging evidence has been obtained during recent years that interferons impact on molecular and cellular mechanisms implicated in the development of vascular proliferative diseases such as atherosclerosis, restenosis, and cardiac allograft vasculopathy. Further appreciation and delineation of the precise mechanisms on how interferons influence vascular proliferative disease processes could potentially facilitate the development of novel treatment options attenuating these common causes of cardiovascular morbidity and mortality.
Wessely
Rainer
R
German Heart Center and 1st Department of Medicine, University of Technology, Munich. rwessely@dhm.mhn.de
D000818:Animals; D050197:Atherosclerosis / Q000276:immunology; D049109:Cell Proliferation; D018450:Disease Progression; D006801:Humans; D007370:Interferon Type I / Q000627:therapeutic use; D007372:Interferons / Q000502:physiology*; D009131:Muscle, Smooth, Vascular / Q000276:immunology / Q000473:pathology; D017471:Receptors, Interferon / Q000378:metabolism; D011994:Recombinant Proteins; D015398:Signal Transduction / Q000502:physiology*; D014652:Vascular Diseases / Q000188:drug therapy / Q000276:immunology*; D014777:Virus Diseases / Q000276:immunology
D007370:Interferon Type I; D017471:Receptors, Interferon; D011994:Recombinant Proteins; D007372:Interferons